Global Nonalcoholic Fatty Liver Disease Therapeutics Market Research Report 2024

Report ID: 1975268 | Published Date: Oct 2024 | No. of Page: 87 | Base Year: 2023 | Rating: 4.5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Oral
        1.2.3 Parenteral
    1.3 Market by Application
        1.3.1 Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Nonalcoholic Fatty Liver Disease Therapeutics Market Perspective (2017-2028)
    2.2 Nonalcoholic Fatty Liver Disease Therapeutics Growth Trends by Region
        2.2.1 Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Nonalcoholic Fatty Liver Disease Therapeutics Historic Market Size by Region (2017-2022)
        2.2.3 Nonalcoholic Fatty Liver Disease Therapeutics Forecasted Market Size by Region (2023-2028)
    2.3 Nonalcoholic Fatty Liver Disease Therapeutics Market Dynamics
        2.3.1 Nonalcoholic Fatty Liver Disease Therapeutics Industry Trends
        2.3.2 Nonalcoholic Fatty Liver Disease Therapeutics Market Drivers
        2.3.3 Nonalcoholic Fatty Liver Disease Therapeutics Market Challenges
        2.3.4 Nonalcoholic Fatty Liver Disease Therapeutics Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Nonalcoholic Fatty Liver Disease Therapeutics Players by Revenue
        3.1.1 Global Top Nonalcoholic Fatty Liver Disease Therapeutics Players by Revenue (2017-2022)
        3.1.2 Global Nonalcoholic Fatty Liver Disease Therapeutics Revenue Market Share by Players (2017-2022)
    3.2 Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Nonalcoholic Fatty Liver Disease Therapeutics Revenue
    3.4 Global Nonalcoholic Fatty Liver Disease Therapeutics Market Concentration Ratio
        3.4.1 Global Nonalcoholic Fatty Liver Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Nonalcoholic Fatty Liver Disease Therapeutics Revenue in 2021
    3.5 Nonalcoholic Fatty Liver Disease Therapeutics Key Players Head office and Area Served
    3.6 Key Players Nonalcoholic Fatty Liver Disease Therapeutics Product Solution and Service
    3.7 Date of Enter into Nonalcoholic Fatty Liver Disease Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Nonalcoholic Fatty Liver Disease Therapeutics Breakdown Data by Type
    4.1 Global Nonalcoholic Fatty Liver Disease Therapeutics Historic Market Size by Type (2017-2022)
    4.2 Global Nonalcoholic Fatty Liver Disease Therapeutics Forecasted Market Size by Type (2023-2028)
5 Nonalcoholic Fatty Liver Disease Therapeutics Breakdown Data by Application
    5.1 Global Nonalcoholic Fatty Liver Disease Therapeutics Historic Market Size by Application (2017-2022)
    5.2 Global Nonalcoholic Fatty Liver Disease Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Nonalcoholic Fatty Liver Disease Therapeutics Market Size (2017-2028)
    6.2 North America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2017-2022)
    6.3 North America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Size (2017-2028)
    7.2 Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2017-2022)
    7.3 Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Nonalcoholic Fatty Liver Disease Therapeutics Market Size (2017-2028)
    8.2 Asia-Pacific Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2017-2022)
    8.3 Asia-Pacific Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Nonalcoholic Fatty Liver Disease Therapeutics Market Size (2017-2028)
    9.2 Latin America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2017-2022)
    9.3 Latin America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Nonalcoholic Fatty Liver Disease Therapeutics Market Size (2017-2028)
    10.2 Middle East & Africa Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2017-2022)
    10.3 Middle East & Africa Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 Merck
        11.1.1 Merck Company Detail
        11.1.2 Merck Business Overview
        11.1.3 Merck Nonalcoholic Fatty Liver Disease Therapeutics Introduction
        11.1.4 Merck Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022)
        11.1.5 Merck Recent Development
    11.2 Pfizer
        11.2.1 Pfizer Company Detail
        11.2.2 Pfizer Business Overview
        11.2.3 Pfizer Nonalcoholic Fatty Liver Disease Therapeutics Introduction
        11.2.4 Pfizer Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022)
        11.2.5 Pfizer Recent Development
    11.3 Novartis
        11.3.1 Novartis Company Detail
        11.3.2 Novartis Business Overview
        11.3.3 Novartis Nonalcoholic Fatty Liver Disease Therapeutics Introduction
        11.3.4 Novartis Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022)
        11.3.5 Novartis Recent Development
    11.4 GlaxoSmithKline
        11.4.1 GlaxoSmithKline Company Detail
        11.4.2 GlaxoSmithKline Business Overview
        11.4.3 GlaxoSmithKline Nonalcoholic Fatty Liver Disease Therapeutics Introduction
        11.4.4 GlaxoSmithKline Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022)
        11.4.5 GlaxoSmithKline Recent Development
    11.5 Allergan
        11.5.1 Allergan Company Detail
        11.5.2 Allergan Business Overview
        11.5.3 Allergan Nonalcoholic Fatty Liver Disease Therapeutics Introduction
        11.5.4 Allergan Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022)
        11.5.5 Allergan Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Oral
    Table 3. Key Players of Parenteral
    Table 4. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 5. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 7. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Region (2017-2022)
    Table 8. Global Nonalcoholic Fatty Liver Disease Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 9. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Region (2023-2028)
    Table 10. Nonalcoholic Fatty Liver Disease Therapeutics Market Trends
    Table 11. Nonalcoholic Fatty Liver Disease Therapeutics Market Drivers
    Table 12. Nonalcoholic Fatty Liver Disease Therapeutics Market Challenges
    Table 13. Nonalcoholic Fatty Liver Disease Therapeutics Market Restraints
    Table 14. Global Nonalcoholic Fatty Liver Disease Therapeutics Revenue by Players (2017-2022) & (US$ Million)
    Table 15. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Players (2017-2022)
    Table 16. Global Top Nonalcoholic Fatty Liver Disease Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Fatty Liver Disease Therapeutics as of 2021)
    Table 17. Ranking of Global Top Nonalcoholic Fatty Liver Disease Therapeutics Companies by Revenue (US$ Million) in 2021
    Table 18. Global 5 Largest Players Market Share by Nonalcoholic Fatty Liver Disease Therapeutics Revenue (CR5 and HHI) & (2017-2022)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Nonalcoholic Fatty Liver Disease Therapeutics Product Solution and Service
    Table 21. Date of Enter into Nonalcoholic Fatty Liver Disease Therapeutics Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 24. Global Nonalcoholic Fatty Liver Disease Therapeutics Revenue Market Share by Type (2017-2022)
    Table 25. Global Nonalcoholic Fatty Liver Disease Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 26. Global Nonalcoholic Fatty Liver Disease Therapeutics Revenue Market Share by Type (2023-2028)
    Table 27. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 28. Global Nonalcoholic Fatty Liver Disease Therapeutics Revenue Market Share by Application (2017-2022)
    Table 29. Global Nonalcoholic Fatty Liver Disease Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 30. Global Nonalcoholic Fatty Liver Disease Therapeutics Revenue Market Share by Application (2023-2028)
    Table 31. North America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 32. North America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 33. Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 34. Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 35. Asia-Pacific Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 36. Asia-Pacific Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Region (2023-2028) & (US$ Million)
    Table 37. Latin America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 38. Latin America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 39. Middle East & Africa Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 40. Middle East & Africa Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 41. Merck Company Detail
    Table 42. Merck Business Overview
    Table 43. Merck Nonalcoholic Fatty Liver Disease Therapeutics Product
    Table 44. Merck Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022) & (US$ Million)
    Table 45. Merck Recent Development
    Table 46. Pfizer Company Detail
    Table 47. Pfizer Business Overview
    Table 48. Pfizer Nonalcoholic Fatty Liver Disease Therapeutics Product
    Table 49. Pfizer Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022) & (US$ Million)
    Table 50. Pfizer Recent Development
    Table 51. Novartis Company Detail
    Table 52. Novartis Business Overview
    Table 53. Novartis Nonalcoholic Fatty Liver Disease Therapeutics Product
    Table 54. Novartis Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022) & (US$ Million)
    Table 55. Novartis Recent Development
    Table 56. GlaxoSmithKline Company Detail
    Table 57. GlaxoSmithKline Business Overview
    Table 58. GlaxoSmithKline Nonalcoholic Fatty Liver Disease Therapeutics Product
    Table 59. GlaxoSmithKline Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022) & (US$ Million)
    Table 60. GlaxoSmithKline Recent Development
    Table 61. Allergan Company Detail
    Table 62. Allergan Business Overview
    Table 63. Allergan Nonalcoholic Fatty Liver Disease Therapeutics Product
    Table 64. Allergan Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022) & (US$ Million)
    Table 65. Allergan Recent Development
    Table 66. Research Programs/Design for This Report
    Table 67. Key Data Information from Secondary Sources
    Table 68. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Type: 2021 VS 2028
    Figure 2. Oral Features
    Figure 3. Parenteral Features
    Figure 4. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Application in 2021 & 2028
    Figure 5. Hospital Case Studies
    Figure 6. Clinic Case Studies
    Figure 7. Others Case Studies
    Figure 8. Nonalcoholic Fatty Liver Disease Therapeutics Report Years Considered
    Figure 9. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 10. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 11. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Region: 2021 VS 2028
    Figure 12. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Players in 2021
    Figure 13. Global Top Nonalcoholic Fatty Liver Disease Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Fatty Liver Disease Therapeutics as of 2021)
    Figure 14. The Top 10 and 5 Players Market Share by Nonalcoholic Fatty Liver Disease Therapeutics Revenue in 2021
    Figure 15. North America Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 16. North America Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Country (2017-2028)
    Figure 17. United States Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 18. Canada Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Country (2017-2028)
    Figure 21. Germany Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. France Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. U.K. Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Italy Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Russia Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Nordic Countries Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Asia-Pacific Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Asia-Pacific Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Region (2017-2028)
    Figure 29. China Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Japan Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. South Korea Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Southeast Asia Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. India Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Australia Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Latin America Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Latin America Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Country (2017-2028)
    Figure 37. Mexico Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Brazil Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Middle East & Africa Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Middle East & Africa Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Country (2017-2028)
    Figure 41. Turkey Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Saudi Arabia Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Merck Revenue Growth Rate in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022)
    Figure 44. Pfizer Revenue Growth Rate in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022)
    Figure 45. Novartis Revenue Growth Rate in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022)
    Figure 46. GlaxoSmithKline Revenue Growth Rate in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022)
    Figure 47. Allergan Revenue Growth Rate in Nonalcoholic Fatty Liver Disease Therapeutics Business (2017-2022)
    Figure 48. Bottom-up and Top-down Approaches for This Report
    Figure 49. Data Triangulation
    Figure 50. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Merck
Pfizer
Novartis
GlaxoSmithKline
Allergan
Frequently Asked Questions
Nonalcoholic Fatty Liver Disease Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Nonalcoholic Fatty Liver Disease Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Nonalcoholic Fatty Liver Disease Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports